Back to News
Market Impact: 0.2
Propanc Reports PRP Activity In Pancreatic Cancer Models, Files Combination Patent Application
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Propanc Biopharma reported preclinical findings that its pancreatic proenzyme formulation (PRP) reduced cancer-cell growth and invasion, including in chemotherapy-resistant pancreatic cancer models. The results are early-stage and do not establish clinical efficacy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PPCB0.55
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- How to Automate Equity Research Workflows: A Control-First Guide
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience